Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesSuppressive Roles of Calreticulin in Prostate Cancer Growth and Metastasis
American Journal of Pathology, 07/20/09
Alur M et al. – The calreticulin mutants containing the P–domain, which binds to other endoplasmic reticulum chaperone proteins, were sufficient for the suppression of PC3 growth in colony formation assays. Overall, the data support the hypothesis that calreticulin inhibits growth and/or metastasis of prostate cancer cells and that this suppression requires the P–domain.
Related Articles
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Relevance Score: 72%
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09
Relevance Score: 71%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 71%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 71%
Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09
Relevance Score: 71%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma
The Prostate, 12/18/09
Differential effect of specific gr/gr deletion subtypes on spermatogenesis in the Chinese Han population
International Journal of Andrology, 12/18/09
Urinary Trypsinogen-2 Dipstick in Acute Pancreatitis
Pancreas, 12/18/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Article Search
Sponsor